Sinaptica Therapeutics announced today that it received FDA breakthrough device designation for its investigational SinaptiStim AD system. Cambridge, Massachusetts-based Sinaptica designed its system to treat cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD). The system creates a novel integration of neurostimulation and brain wave monitoring technologies. It combines those with a proprietary […]
